Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To conduct a comprehensive, systematic review of studies assessing the significance of lipoprotein-associated phospholipase A2 in cardiovascular diseases (CVDs). MATERIAL AND METHODS: A review of the literature was performed using the search term "Lipoprotein-associated phospholipase A2 (Lp-PLA2)" and each of the following terms: "cardiovascular risk," "cardiovascular death," "atherosclerotic disease," "coronary events," "transient ischemic attack (TIA)," "stroke," and "heart failure." The searches were performed on Medline, Google Scholar and ClinicalTrials.gov. RESULTS: The majority of published studies showed a significant association between Lp-PLA2 levels and cardiovascular events after multivariate adjustment. The association was consistent across a wide variety of subjects of both sexes and different ethnic backgrounds. CONCLUSIONS: The role of Lp-PLA2 as a significant biomarker of vascular inflammation was confirmed, and Lp-PLA2 seems to be closely correlated to cardiovascular events. It may be an important therapeutic target and may have an important role in prevention, risk stratification and personalised medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292 · cited 1×
“C-reactive protein was the soluble marker most reproducibly associated with cardiovascular risk (Ridker et al., 2005).”
BackgroundPrevalence of Conventional Risk Factors in Patients With Coronary Heart Disease
Khot, U. N. (2003) · JAMA · doi:10.1001/jama.290.7.898 · Cited by 1,494
Lipids, risk factors and ischaemic heart disease
Castelli, W. P. (1996) · Atherosclerosis · doi:10.1016/0021-9150(96)05851-0 · Cited by 337
Garza, C. A., Montori, V. M., McConnell, J. P., Somers, V. K., Kullo, I. J., & Lopez-Jimenez, F. (2007) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60992-0 · Cited by 159
Rosenson, R. S. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.12.012 · Cited by 30
Cited by
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
Oxidative Stress and Epilepsy: Literature Review
Aguiar, C. C. T., Almeida, A. B., Araújo, P. V. P., Abreu, R. N. D. C. D., Chaves, E. M. C., Vale, O. C. D., Macêdo, D. S., Woods, D. J., Fonteles, M. M. D. F., & Vasconcelos, S. M. M. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/795259 · Cited by 322
Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy
Wiklund, O., Pirazzi, C., & Romeo, S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0397-8 · Cited by 45
Nasopoulou, C., Karantonis, H. C., Detopoulou, M., Demopoulos, C. A., & Zabetakis, I. (2014) · Phytochemistry Reviews · doi:10.1007/s11101-014-9350-8 · Cited by 26
Metadata
- Authors
- Vittos, O., Toana, B., Vittos, A., & Moldoveanu, E.
- Venue
- Biomarkers
- Publisher
- Informa UK Limited
- Published
- 2012-03-09
- Volume
- 17
- Issue
- 4
- Pages
- 289-302
- ISSN
- 1354-750X (ISSN-L)
- 1366-5804
- OpenAlex
- W2015926309
- Cited by
- 56
- References
- 5
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker. https://app.cochat.ai/papers/10.3109/1354750x.2012.664170
- The paper
- Vittos, O., Toana, B., Vittos, A., & Moldoveanu, E. (2012). Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker. Biomarkers. https://doi.org/10.3109/1354750x.2012.664170
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.